Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2735481 | 0.83 | LMNA (0.35) | TSHRMAPTPOLB | |
| SCHEMBL1498188 | 0.83 | MAPT (0.47) | TSHRMAPTTP53ALDH1A1ELANE | |
| Isopropyl Alcohol SCHEMBL28680436 | 0.81 | TSHR (0.48) | TSHRMAPTALDH1A1 | |
| SCHEMBL20307204 | 0.80 | TSHR (0.36) | TSHRMAPTALDH1A1ELANEPOLB | |
| SCHEMBL41548 | 0.80 | TSHR (0.52) | TSHRMAPTALDH1A1 | |
| SCHEMBL13168166 | 0.80 | TSHR (0.36) | TSHRMAPTALDH1A1ELANEPOLB | |
| SCHEMBL9154017 | 0.79 | TSHR (0.32) | TSHRMAPT | |
| SCHEMBL5604725 | 0.79 | GRIN2D (0.37) | TSHRMAPT | |
| SCHEMBL28484563 | 0.79 | TSHR (0.32) | TSHRMAPT | |
| SCHEMBL18270557 | 0.78 | TSHR (0.34) | TSHRMAPTALDH1A1ELANEPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142627-A1 | MONOPHOSPHATE PRODRUGS OF DAPD AND ANALOGS THEREOF | EMORY UNIVERSITY (US) | 2012-06-07 | — | — | US | disclosed |
| US-20100210840-A1 | STEREOSELECTIVE PROCESS FOR PREPARING PURINE DIOXOLANE NUCLEOSIDE DERIVATIVES | RFS PHARMA, LLC | 2010-08-19 | — | — | US | disclosed |
| EP-1648894-B1 | METHOD FOR THE PRODUCTION OF OH PROTECTED [4-(2.6-DIAMINO-9H-PURINE-9-YL)- 1.3-DIOXOLANE-2-YL]METHANOL DERIVATIVES | WACKER CHEMIE AG (DE) | 2007-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210840-A1 | STEREOSELECTIVE PROCESS FOR PREPARING PURINE DIOXOLANE NUCLEOSIDE DERIVATIVES | PNP, NUDT1, GART | TSHR 4270/4885MAPT 4628/4885TP53 4237/4885 |
| US-20120142627-A1 | MONOPHOSPHATE PRODRUGS OF DAPD AND ANALOGS THEREOF | DCTD, ENTPD5, PNP | TSHR 3698/4885MAPT 3091/4885TP53 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.